C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/195 (2006.01) A61K 39/02 (2006.01) A61P 31/04 (2006.01) C12N 1/20 (2006.01) C12Q 1/00 (2006.01) G01N 33/53 (2006.01) G01N 33/569 (2006.01)
Patent
CA 2455701
This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O- polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted "survivor" antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post- translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD50s of F. tularensis LVS.
Berger Bradley
Cherwonogrodzky John W.
Sikora Christopher
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence
Nelligan O'brien Payne Llp
LandOfFree
The use of cross-protection to identify novel vaccine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with The use of cross-protection to identify novel vaccine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The use of cross-protection to identify novel vaccine... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1588237